Table 2.
Share of preference and scenario analysis results.
| Share of Preference | Base Scenario |
Scenario 1 |
Scenario 2 |
Scenario 3 |
Scenario 4 |
Scenario 5 |
Scenario 6 |
Scenario 7 |
Scenario 8 |
|---|---|---|---|---|---|---|---|---|---|
| United States | |||||||||
| Vaccine varieties | Inactivated vaccine | Adenovirus vaccine | mRNA | mRNA | Inactivated vaccine | Adenovirus vaccine | Adenovirus vaccine | Adenovirus vaccine | mRNA |
| Adverse effect | moderate | Very mild | Moderate | Mild | Very mild | Mild | Very mild | Very mild | Very mild |
| Efficacy | 55% | 75% | 95% | 95% | 75% | 95% | 65% | 75% | 95% |
| Time for the vaccine to start working | 20 days | 20 days | 20 days | 20 days | 10 days | 20 days | 5 days | 5 days | 5 days |
| The duration of vaccine effectiveness | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 20 months |
| The cost of vaccination | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 |
| Share of preference | 2.9% | 8.2% | 14.2% | 17.3% | 7.7% | 16.2% | 5.2% | 9.2% | 19.1% |
| China | |||||||||
| Vaccine varieties | Adenovirus vaccine | Adenovirus vaccine | mRNA vaccine | mRNA vaccine | Inactivated vaccine | Adenovirus vaccine | Adenovirus vaccine | Adenovirus vaccine | Inactivated vaccine |
| Adverse effect | moderate | Very mild | Moderate | Mild | Very mild | Mild | Very mild | Very mild | Very mild |
| Efficacy | 55% | 75% | 95% | 95% | 75% | 95% | 65% | 75% | 95% |
| Time for the vaccine to start working | 20 days | 20 days | 20 days | 20 days | 10 days | 20 days | 5 days | 5 days | 5 days |
| The duration of vaccine effectiveness | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 5 months | 20 months |
| The cost of vaccination | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 | USD 50 |
| Share of preference | 4.5% | 10.7% | 9.4% | 13.4% | 13.7% | 12.4% | 7.9% | 10.6% | 17.6% |